u/marisol_kravchenko

I would not change the programme on the strength of one scan. The measurement error is larger than the effect you are reacting to.

private and NHS pathways are not a ladder, they are separate routes

a shortage in one member state is not a shortage in all of them

private pricing varies enormously between neighbouring countries

the Irish scheme cap is the single most useful fact in this board

The two routes, described separately, because mixing them is where most of the confusion here starts.

Disagreeing with this line: that is the arrangement in one nation and the question is about another.

Correction: that threshold is your ICB’s, not a national one. They differ and they change by year.

Two years and four months on a tier 3 list. Referral date and every letter kept, which turned out to matter when the service reorganised.

Yes — four nations, four pathways, and threads that ignore that give people the wrong answer confidently.

Disagree — slower loss does not automatically preserve lean mass.

Disagreeing with this line: rate alone does not preserve lean mass. The training does.

Nothing on this board is medical advice, and the people answering you — including me — are members with spreadsheets rather than clinicians.

What does the wiki page on this say — genuinely asking, not deflecting?

Cosigning on cross-border prescriptions. The rules exist and they are narrower than the summaries suggest.

Yes — the withdrawal literature is consistent and it is a pharmacological finding, not a moral one.

Removed the taper schedule written for another member.

Adding the one process step — write down where you are before you change anything.

Has the appetite changed, even if the scale has not?

the EMA authorises, member states decide who pays

Not convinced — cross-border prescription recognition is narrower than you are describing and the exceptions matter.

Two years and four months on a tier 3 list. Referral date and every letter kept, which turned out to matter when the service reorganised.

Careful — you have a plausible mechanism and no evidence that it is the operative one in the case you are describing.

search first, but a repeat question is not a crime

Adding the one habit worth starting today: write the concentration on the vial.

Went looking for human data on a mechanism everybody here asserts. Found preclinical work and one small study. That was clarifying.

the reimbursement criteria are published in most member states

Correction: that is glucose-dependent insulin secretion, which is why hypoglycaemia risk is low as monotherapy. Not the same claim as you made.

say which country or the thread is useless

the Irish scheme cap is the single most useful fact in this board